Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
Bicara Therapeutics (Nasdaq: BCAX) announced it will report its second quarter 2026 financial results and provide business updates before the market opens on Tuesday, August 11, 2026.
Rhea-AI Summary
Bicara Therapeutics (Nasdaq: BCAX) announced it will report its second quarter 2026 financial results and provide business updates before the market opens on Tuesday, August 11, 2026. The company will host a conference call at 8:30 a.m. ET the same day to discuss these updates.
Investors can register online to receive dial-in details and a unique PIN for the call. A live webcast will be available via the “Events & Presentations” section of the Investors page on the Bicara website, with a replay accessible for 30 days following the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BCAX
In the Aug 4 session, BCAX gained 1.40%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting period
- Second quarter 2026
- Financial results and business updates
- Report date
- August 11, 2026
- Before the market opens
- Conference call time
- 8:30 a.m. ET
- August 11, 2026
- Webcast replay
- 30 days
- Following the event
Previous Earnings date Reports
-
Scheduled first-quarter results and business update before the market open
-
Scheduled fourth-quarter and full-year results with business updates
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report second quarter 2026 financial results and business updates before the market opens on Tuesday, August 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.
Contacts
Investors
Rachel Frank
IR@bicara.com
Media
Tim Palmer
tim.palmer@bicara.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.